It has been three years since FDA launched the Sentinel Initiative and, since then, FDA has made significant progress. On September 7, the Engelberg Center hosted the first of the three-part Sentinel Initiative 101 Webinar Series, “Overview of FDA’s Sentinel Initiative” to review ongoing activities and accomplishments. The roundtable featured a presentation from Dr. Judy Racoosin, Sentinel Initiative Scientific Lead, Office of Medical Policy, Center for Drug Evaluation and Research, U.S. Food and Drug Administration.
Dr. Racoosin’s presentation provided a high-level review of the Sentinel Initiative’s scope and achievements including:
- FDA’s 3-year vision for the Sentinel Initiative
- A brief overview of the role of the Mini-Sentinel pilot, the Observational Medical Outcomes Partnership, the Federal Partners Collaboration, and the Brookings Institution cooperative agreement
- Next steps for the Sentinel Initiative
Subsequent webinars in this series will provide a more in-depth overview of these pilot activities.